Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.54 |
| ▸ | USP2 | O75604 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.48 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081032 | 0.90 | CYP3A4 (0.56) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3079273 | 0.88 | ALDH1A1 (0.51) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3086931 | 0.87 | ALDH1A1 (0.55) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3083741 | 0.87 | ALDH1A1 (0.50) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3075559 | 0.87 | ALDH1A1 (0.50) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3080049 | 0.87 | PROKR1 (0.53) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3086922 | 0.84 | ALDH1A1 (0.49) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3073923 | 0.83 | MEN1 (0.48) | CYP3A4USP2TSHRALDH1A1HPGD | |
| SCHEMBL3086716 | 0.83 | HTR1A (0.50) | CYP3A4ALDH1A1HPGDCYP2C19KMT2A | |
| SCHEMBL3081026 | 0.82 | LMNA (0.53) | CYP3A4ALDH1A1HPGDCYP1A2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790898-B2 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2010-09-07 | — | — | US | claimed |
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-07-26 | — | — | US | claimed |
| US-7790898-B2 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | GRUENENTHAL GMBH (DE) | 2007-07-26 | — | — | US | disclosed |
| EP-1771417-A1 | SUBSTITUTED 3-PHENYLPIPERIDINE DERIVATIVES | Grünenthal GmbH (DE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010577-A1 | SUBSTITUTED 3-PHENYLPIPERIDINE DERIVATIVES | Grünenthal GmbH (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173533-A1 | Substituted 3-phenylpiperidine compounds, their preparation and use | OPRK1, OPRD1, OPRL1 | CYP3A4 113/4885USP2 4164/4885TSHR 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.